. 2015 Oct 28;88(1056):20150658. doi: 10.1259/bjr.20150658

Table 2.

Literature review of stereotactic body radiotherapy late (>6 months) toxicity outcomes

Study	n	Median follow-up (months)	Gastrointestinal	Genitourinary	Sexual
Rivin del Campo et al³⁹	477	72		RTOG Grade 3: 1.7%
King et al¹⁸	304	60	RTOG Grade 2: 4.51%	RTOG Grade 2: 8.18% Grade 3: 1.64%	Percentage developed ED: 25%
Sher et al²⁵	269	36		CTCAE v. 3 Grade ≥2: 41.4% Grade 3: 1.5%
Katz and Kang⁴⁰	100	36	RTOG Grade 1: 2% Grade 2: 1%	RTOG Grade 1: 4% Grade 2: 3% Grade 3: 1%
Mirallbell et al²⁴	100	27.6	CTCAE v. 3 Grade 1: 11%	CTCAE v. 3 Grade 1: 26% Grade 2: 17% Grade 3: 1%	Percentage developed ED: 21%
Obayomi-Davies et al⁴¹	84	50.8	RTOG Grade 2: 7.14% Grade 4: 1.19%	RTOG Grade 2: 5.95%
Resnick et al⁴²	67	32.4	RTOG Grade 1: 14% Grade 2: 2% Grade 3 0%	RTOG Grade 1: 23% Grade 2: 5% Grade 3: 3.5%
Kupelian et al²⁶	56	35.5		CTCAE v. 4 Grade 1: 19.6% Grade 2: 19.6% Grade 3: 3.6%
Gomez et al⁴³	32	35.5			Percentage developed ED: 33%
Wiegner and King⁴⁴	97	32.4			Percentage developed ED: 45.6%
Marien et al³⁶	864	36	EPIC-26 bowel −0.85 points at 3 years	EPIC-26 urinary +0.4 points at 3 years	EPIC-26 sexual −7.3 points at 3 years
Kim et al⁴⁵	228	45.6	EPIC-26 bowel −0.8 points at 2 years	EPIC-26 urinary −1.9 points at 2 years	EPIC-26 sexual −7.5 points at 2 years
Jones et al³⁷	174	46.8	EPIC-26 bowel −2.4 points at 3 years	EPIC-26 urinary −2.5 points at 3 years	EPIC-26 sexual −7.5 points at 2 years

CTCAE, common terminology criteria for adverse events; ED, erectile dysfunction; EPIC-26, Expanded Prostate Cancer Index Composite-26; RTOG, Radiation Therapy and Oncology Group.